Krystal Biotech Q2 2024 Adj. EPS $0.53 Misses $0.58 Estimate, Sales $70.284M Beat $65.335M Estimate
Portfolio Pulse from Benzinga Newsdesk
Krystal Biotech reported Q2 2024 adjusted EPS of $0.53, missing the estimate of $0.58. However, the company beat sales estimates with $70.284 million compared to the expected $65.335 million.
August 05, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Krystal Biotech's Q2 2024 earnings report showed a mixed performance with EPS missing estimates but sales exceeding expectations.
The mixed results, with EPS missing but sales beating estimates, suggest a neutral short-term impact on the stock price. Investors may weigh the positive sales performance against the EPS miss.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100